Phase II RA media
https://psychedelicinvest.com/incannex-commences-dosing-in-phase-2-clinical-trial-assessing-ihl-675a-in-patients-with-rhemetoid-arthritis/
“Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A. Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options. IHL-675A has the potential to address this unmet need. We look forward to generating data on the safety and efficacy of IHL-675A and sharing this data with FDA and other regulatory agencies.”
- Chief Scientific Officer of Incannex, Dr. Mark Bleackley
recap:
General discussion, page-19136
-
- There are more pages in this discussion • 1,275 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)